Zhao Y, Davis H W
Department of Internal Medicine (Pulmonary & Critical Care Medicine), University of Cincinnati Medical Center, Ohio 45267-0564, USA.
J Cell Physiol. 1996 Nov;169(2):350-7. doi: 10.1002/(SICI)1097-4652(199611)169:2<350::AID-JCP14>3.0.CO;2-D.
Myristoylated alanine-rich C kinase substrates (MARCKS) is a prominent protein kinase C (PKC) substrate that is targeted to the plasma membrane by an aminoterminal myristoyl group. In its nonphosphorylated form, MARCKS cross-links Factin and binds calmodulin (CaM) reciprocally. However, upon phosphorylation by PKC, MARCKS release the actin or CaM MARCKS may therefore act as a CaM sink in resting cells and regulate CaM availability during cell activation. We have demonstrated previously that thrombin-induced myosin light chain (MLC) phosphorylation and increased monolayer permeability in bovine pulmonary artery endothelial cells (BPAEC) require both PKC-and CaM-dependent pathways. We therefore decided to investigate the phosphorylation of MARCKS in BPAEC to ascertain whether this occurs in a temporally relevant manner to participate in the thrombin-induced events. MARCKS is phosphorylated in response to thrombin with a time course similar to that seen with MLC. As expected, MARCKS is also phosphorylated by phorbol 12-myristate 13 acetate (PMA), a PKC activator, but with a slower onset and more prolonged duration. Bradykinin also enhances MARCKS phosphorylation in BPAEC, but histamine does not. MARCKS is distributed evently between the membrane and cytosol in BPAEC, and neither thrombin nor PMA caused significant translocation of the protein. Specific PKC inhibitors attenuated MARCKS phosphorylation by either thrombin or PMA. Since thrombin-induced MLC phosphorylation is also attenuated by these inhibitors, MARCKS may be involved in MLC kinase activation and subsequent BPAEC contraction. W7, a CaM antagonist, enhances the phosphorylation of MARCKS. This was expected since CaM binding to MARCKS has been shown to decrease MARCKS phosphorylation by PKC. On the other hand, tyrosine kinase inhibitors, genistein and tyrphostin, attenuate MARCKS phosphorylation but have no effect on MLC phosphorylation, suggesting that MARCKS may be phosphorylated by kinases other than PKC. Phosphorylation of MARCKS outside the PKC phosphorylation domain would not be expected to induce the release of CaM. These data provide support for the hypothesis that MARCKS may serve as a regulator of CaM availability in BPAEC.
富含豆蔻酰化丙氨酸的蛋白激酶C底物(MARCKS)是一种重要的蛋白激酶C(PKC)底物,其通过氨基末端的豆蔻酰基靶向定位于质膜。在其非磷酸化形式下,MARCKS使肌动蛋白交联并与钙调蛋白(CaM)相互结合。然而,在被PKC磷酸化后,MARCKS会释放肌动蛋白或CaM。因此,MARCKS在静息细胞中可能充当CaM库,并在细胞激活过程中调节CaM的可用性。我们之前已经证明,凝血酶诱导的牛肺动脉内皮细胞(BPAEC)中肌球蛋白轻链(MLC)磷酸化和单层通透性增加需要PKC和CaM依赖的途径。因此,我们决定研究BPAEC中MARCKS的磷酸化情况,以确定其是否以与时间相关的方式参与凝血酶诱导的事件。MARCKS在凝血酶作用下发生磷酸化,其时间进程与MLC相似。正如预期的那样,MARCKS也会被PKC激活剂佛波酯12 - 肉豆蔻酸酯13 - 乙酸酯(PMA)磷酸化,但起始较慢且持续时间更长。缓激肽也能增强BPAEC中MARCKS的磷酸化,但组胺则不能。MARCKS在BPAEC的膜和胞质溶胶中均匀分布,凝血酶和PMA均未引起该蛋白的显著转位。特异性PKC抑制剂可减弱凝血酶或PMA诱导的MARCKS磷酸化。由于这些抑制剂也会减弱凝血酶诱导的MLC磷酸化,因此MARCKS可能参与MLC激酶激活及随后的BPAEC收缩。CaM拮抗剂W7可增强MARCKS的磷酸化。这是预期的结果,因为已表明CaM与MARCKS结合会降低PKC对MARCKS的磷酸化。另一方面,酪氨酸激酶抑制剂染料木黄酮和 tyrphostin可减弱MARCKS磷酸化,但对MLC磷酸化无影响,这表明MARCKS可能被PKC以外的激酶磷酸化。在PKC磷酸化结构域之外的MARCKS磷酸化预计不会诱导CaM的释放。这些数据为MARCKS可能作为BPAEC中CaM可用性调节剂的假说提供了支持。